leisure time -WSS

leisure time

author：knowledge 2025-10-01 04:10:43 - browse：9

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： 15 die by electrocution after transformer explodes in northern India

entertainment

WSS

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

STAT Virtual Event: The State of Biosimilars: What to Watch

A look at other Americans who have crossed into North Korea over the years

US soldier in North Korean custody after crossing DMZ line

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

How dance can help nurses traumatized by Covid

knowledge

leisure time

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Google and Epic fight stronger regulation of AI in health care

Medicare proposal to cover medical devices draws a mixed reaction

A public scorecard can help hold safety

Alkermes shareholders re

Why you get paid to donate plasma but not blood

George Santos makes 1st court appearance after pleading not guilty to 13 counts

As digital health tech proliferates, a new institute aims to cut through hype

BioMarin wins approval for gene therapy to treat hemophilia A

FDA seeking to stop procedures at two unregulated stem cell clinics

hotspot

US soldier in North Korean custody after crossing DMZ line

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Sanofi seeks simpler, safer CRISPR sickle cell cure

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

explore

entertainment

hotspot

Wikipedia